Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion type Assertion NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_head.
- NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion description "[Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_provenance.
- NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion evidence source_evidence_literature NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_provenance.
- NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion SIO_000772 18587431 NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_provenance.
- NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion wasDerivedFrom befree-20140225 NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_provenance.
- NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_assertion wasGeneratedBy ECO_0000203 NP894814.RA4ICg0FVHnE8EZJXawAUe3pTVUv64-4vvpBVtCBu3h1k130_provenance.